Home » CSMC GRANTS RIGHTS OVER RIFAXIMIN TO SALIX
CSMC GRANTS RIGHTS OVER RIFAXIMIN TO SALIX
July 12, 2006
Salix Pharmaceuticals, Ltd. announced that the company has entered into an agreement with Cedars-Sinai Medical Center, (CSMC), for the right to use US Patent No. 6,861,053 and US Patent Application No. 11/234,516 relating to methods of diagnosis and treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth. ()A HREF="http://pharmabiz.com/article/detnews.asp?articleid=34142" TARGET="_blank">PharmaBiz
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct